Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-10-10
2006-10-10
Siew, Jeffrey (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S389100
Reexamination Certificate
active
07119174
ABSTRACT:
The present invention relates to AUR1 and/or AUR2 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for AUR1 and/or AUR2 related diseases or conditions characterized by an abnormal interaction between a AUR1 and/or AUR2 polypeptide and a AUR1 and/or AUR2 binding partner.
REFERENCES:
patent: 4343940 (1982-08-01), Kreighbaum et al.
patent: 4376110 (1983-03-01), David et al.
patent: 4447608 (1984-05-01), Jones et al.
patent: 4757072 (1988-07-01), Kabbe et al.
patent: 4945050 (1990-07-01), Sanford et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5283173 (1994-02-01), Fields et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5316553 (1994-05-01), Kaul et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 0 520 722 (1992-12-01), None
patent: 0 562 734 (1993-09-01), None
patent: 0 566 226 (1993-10-01), None
patent: WO 91/15495 (1991-10-01), None
patent: WO 92/14748 (1992-09-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 92/21660 (1992-12-01), None
patent: WO 93/09236 (1993-05-01), None
patent: WO 94/03427 (1994-02-01), None
patent: WO 94/14808 (1994-07-01), None
patent: WO 94/23039 (1994-10-01), None
patent: WO 96/34985 (1996-08-01), None
patent: WO 96/22976 (1996-11-01), None
Niwa et al. Gene, 1996, 169:197-201.
Campbell, A. “Monoclonal Technology”, Laboratory Techniques in Biochemistry and Molecular Biology, 1948, 13:1-32.
Vankayalapati et al. Molecular Cancer Therapeutics, 2003, 2:283-294.
Niwa et al (Gene, Mar. 1996, 169:197-201).
Campbell (“Monoclonal Antibody Technology”, Laboratory Techniques in Biochemistry and Molecular Biology, 1984, 13:1-32).
Abe et al., “Molecular Characterization of a Novel Metabotropic Glutamate Receptor mGluR5 Coupled to Insitol Pohosphate/Ca2+ Signal,”J. Biol. Chem., 1992, pp. 13361-13368, vol. 267, No. 19.
Alberts et al.,Molecular Biology of the Cell, Second Edition, published 1989, by Garland Publishing (New York), pp. 265-266 (Table of Contents Only).
Allen et al., “Modulation of CD4 by suramin,”Clin. Exp. Immunol., 1991, pp. 141-146, vol. 91.
Altschul et al., “Basic Local Alignment Search Tool,”J. Mol. Biol., 1990, pp. 403-410, vol. 215.
Anafi et al., “Tyrphostin-Induced Inhibition of p210bcr-ablTyrosine Kinase Activity Induces K562 to Differentiate,”Blood, 1993, pp. 3524-3529, vol. 82.
Baker et al., “Induction of acetylcholine receptor clustering by native polystyrene beads,”Journal of Cell Science, 1992, pp. 543-555, vol. 102.
Barker et al., “In vitro activity of non-glutamate containing quinazoline-based thymidylate sunthase inhibitors,”Proceedings of the American Association for Cancer Research, 1991, p. 327 at abstract No. 1939, vol. 32.
Bayer et al., “The Avidin-Biotin Complex in Affinity Cytochemistry,”Methods in Enzymology, 1979, pp. 308-319, vol. 62.
Benoist et al., “In vivo sequence requirements of the SV40 early promoter region,”Nature, 1981, pp. 304-310, vol. 290.
Bertino et al., “Toward improved selectivity in cancer chemotherapy: the Richard and Hinda Rosenthal Foundation Award Lecture,”Cancer Research, 1979, pp. 293-304, vol. 39.
Bigner et al., “Structural chromosomal abnormalities in human medulloblastoma,”Cancer Genet. Cytogenet., 1988, pp. 91-101, vol. 30.
Bilder et al., “Tyrophostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells,”Am. J. Physiol., 1991, pp. C721-C730, vol. 260, vol. 29.
Bockmuhl et al.,Laryngorhinootologie, 1996, pp. 408-414, vol. 75.
Bollon et al., “DNA transformation efficiency of various bacterial and yeast host-vector systems,”Journal of Clinical Hematology and Oncology, 1980, pp. 39-487, vol. 10, Nos. 2 & 3.
Botstein et al., “Making mutations in vitro and putting them back into yeast,”Miami Winter Symposia—From Gene to Protein: Translation into Biotechnology, edited by Ahmad et al., 1982, pp. 265-274, vol. 19, Academic Press.
Brinster et al., “Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs,”Proc. Natl. Acad. Sci. USA, 1985, pp. 4438-4442, vol. 82.
Broach et al., “The Yeast Plasmid 2μ Circle,”Cell, 1982, pp. 203-204, vol. 28.
Broach,The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance, 1981, pp. 445-470, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
Bryckaert et al.,Experimental Cell Research, 1992, pp. 255-261, vol. 199.
Bullock et al.,Techniques in Immunocytochemistry, vol. 1 (1982), vol. 2 (1982), vol. 3 (1985), Academic Press, Orlando, FL (Table of Contents Only).
Burke et al., “Arylamides of Hydroxlated Isoquinolines as Protein-Tyrosine Kinase Inhitors,”Bioorganic&Medical Chemistry Letters, 1992, pp. 1771-1774, vol. 2, No. 12.
Burke et al., “Bicyclic Compounds as Ring-Constrained Inhibitors of Protein-Tyrosine Kinase p56lck 1,”Journal of Medicinal Chemistry, 1993, pp. 425-432, vol. 36, No. 4.
Burke, et al.J. Med. Chem., 36:425-432 (1993).
Capecchi, “Altering the Genome by Homologous Recombination,”Science, 1989, pp. 1288-1292, vol. 244.
Capecchi, “High Efficiency Transformation by Direct Microinjection of DNA into Cultured Mammalian Cells,”Cell, 1980, pp. 479-488, vol. 22.
Chan et al., “Isolation and Characterization of Chromosome—Gain and Increase—in—Ploidy Mutants in Yeast,”Genetics, 1993, pp. 677-691, vol. 135.
Chard,An Introduction to Radioimmunoassay and Related Techniques, 1986, Elsevier Science Publishers, Amsterdam, The Netherlands.
Chater et al.,Sixth International Symposium on Actinomycetales Biology, 1986, pp. 45-54, Akademiai Kaido, Budapest, Hungary.
Chen, “High-Efficiency Transformation of Mammalian Cells by Plasmid DNA,”Molecular and Cellular Biology, 1987, pp. 2745-2754, vol. 7, No. 8.
Chomczynski et al., “Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction,”Analytical Biochemistry, 1987, pp. 156-159, vol. 162.
Chu et al., “Electroporation for the efficient transfection of mammalian cells with DNA,”Nucleic Acids Research, 1987, pp. 1311-1326, vol. 15.
Courjal et al., “DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours,”British Journal of Cancer, 1996, pp. 1984-1989, vol. 74.
Cowley et al., “Activation of MAP Kinase Kinase is Necessary and Sufficient for PC12 Differentiation and for Transformation of NIH 3T3 Cells,”Cell, 1994, pp. 841-852, vol. 77.
Curiel et al., “Gene Transfer to Respiratory Epithelial Cells via the Receptor-mediated Endocytosis Pathway,”Am. J. Respir. Cell. Mol. Biol., 1992, pp. 247-252, vol. 6.
Curtin et al., “Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717,”Br. J. Cancer, 1986, pp. 361-368, vol. 53.
Dolle et al., “5,7-Dimethoxy-3-(4-pyridinyl)auinoline is a Potent and Selective Inhibitor of Human Vascular—Type Platelet—Derived Growth Factor Receptor Tyrosine Kinase,”J. Med. Chem., 1994, pp. 2627-2629, vol. 37.
Dong et al., “Protein Tyrosine Kinase Inhibitors Decrease Induction of Nitric Oxide Synthase Activity in Lipopolysaccharide-Responsive and Lipopolysaccharide-Nonresponsive Murine Macrophages,”The Journal of Immunology151(5):2717-2724 (1993).
Dong et al., “Activation of tumoricidal properties in macrophages by lipopolysaccharide requires protein—tyrosine kinase activity,”Journal of Leukocyte Biology, 1993, pp. 53-60, vol. 53.
Elledge, “Cell Cycle Checkpoints: Preventing an
Bishoff James
Plowman Gregory
Aeder Sean E
Siew Jeffrey
Sugen Inc.
LandOfFree
Diagnosis and treatment of AUR1 and/or AUR2 related disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnosis and treatment of AUR1 and/or AUR2 related disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosis and treatment of AUR1 and/or AUR2 related disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3657485